Mesoblast Ltd (MESO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $15.05 (+1.21%), Market cap $1.92B, 52-week low–high $10.16 ~ $20.96.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain
Financial statements, price targets, institutional (13F) holdings and related news for Mesoblast Ltd are updated in real time on BlackAll Trade.
Mesoblast Ltd trades at $15.05 (+1.21%). Real-time quotes and charts are available on BlackAll Trade.
Mesoblast Ltd has a market cap of about $1.92B.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary r